(redirected from PCV7)
Also found in: Dictionary, Thesaurus, Medical, Acronyms.
Related to PCV7: Polio vaccine


see vaccinationvaccination,
means of producing immunity against pathogens, such as viruses and bacteria, by the introduction of live, killed, or altered antigens that stimulate the body to produce antibodies against more dangerous forms.
..... Click the link for more information.



a preparation obtained from microorganisms (bacteria, rickettsias, viruses) or products of their activity and used for active immunization of human beings and animals for prophylactic and therapeutic purposes. Vaccine was first used in 1796 by the English physician E. Jenner, who inoculated persons with cowpox, or vaccinia (hence the name “vaccine”) to protect them against smallpox.

Live, killed, and chemical vaccines and toxoids are distinguished.

Live vaccines are made from specially attenuated cultures of microorganisms deprived of their capacity to cause disease but remaining capable of reproducing in the body and causing immunity. The first to create live vaccines against anthrax (1881) and rabies (1885) was the French microbiologist L. Pasteur. The live tuberculosis vaccine (BCG) proposed in 1926 by the French scientists A. Calmette and C. Guérin won universal recognition; it greatly reduced the tuberculosis rate. Many live vaccines were created by Soviet scientists: for example, typhus vaccine (P. F. Zdrodovskii, 1957-59), influenza vaccine (A. A. Smorodintsev, V. D. Solov’ev, and V. M. Zhdanov, 1960), brucellosis vaccine (P. A. Vershilova, 1947-51), and smallpox vaccine (M. A. Morozov, 1941-60). Vaccines are the only effective inoculative preparations for certain diseases (rabies, smallpox, plague, tularemia). Live vaccines generally produce long-lasting immunity.

Killed vaccines are made from microorganisms killed by physical methods (heating) or chemical methods (phenol, formaldehyde, acetone). Killed vaccines are used to prevent only those diseases for which live vaccines are not available (typhoid, paratyphoid B, whooping cough, cholera, tick-borne encephalitis). They provide less protection than live vaccines. Hence immunity develops only after a course of immunization (vaccination) consisting of several inoculations.

Chemical vaccines are substances isolated from bacterial cells by various chemical methods and containing the main elements that cause immunity. Chemical vaccines against intestinal infections were first employed in 1941 as part of the NIISI polyvalent vaccine proposed by the Soviet scientists N. I. Aleksandrov and N. E. Gefen. Chemical vaccines are used to provide protection against paratyphoid B, typhoid, and rickettsial diseases.

The development of immunity following the injection of toxoids results from the appearance in the blood of antibodies that neutralize the effect of a particular toxin. Toxoids were obtained for the first time during the years 1923-26 by the French scientist G. Ramon. Toxoids are used to prevent diphtheria, tetanus, botulism, gas gangrene, and staphylococcal infections.

Vaccines can be made from the causative agent of a single infection, so-called monovalent vaccines, or from a combination of two or more causative agents, polyvalent vaccines. The latter produce immunity to several infectious diseases.

There are various methods of administering vaccines. In the case of live vaccines, they are related to a certain extent to the routes by which the causative agents enter the body. Thus, poliomyelitis vaccine is administered orally; influenza vaccine intranasally; smallpox, anthrax, and tularemia vaccines epidermally; brucellosis vaccine intradermally; typhus vaccine subcutaneously. Killed vaccines and toxoids are injected subcutaneously or intramuscularly.

Live vaccine is used to treat rabies (vaccine therapy), the only method of protecting man from this fatal disease. Autovaccines are used to treat several chronic inflammatory diseases caused by staphylococci and streptococci.

In the USSR, vaccines are produced by scientific production institutions. The quality of the preparations is controlled by the L. A. Tarasevich State Control Institute for Biomedical Preparations in Moscow.


Vaccines in veterinary medicine. The principles used in preparing and classifying vaccines for the treatment of animal diseases are the same as those for human diseases. The most widely used live vaccines in veterinary practice include anthrax vaccines—STI and GNKI; swine erysipelas vaccine —from the Konev strain and VR2; brucellosis vaccine— from strain 19; and vaccines against cholera, smallpox, and Newcastle disease. Killed vaccines are used to prevent and treat more than 20 infectious diseases of animals.


Ramon, G. Sorok let issledovatel’skoi raboty. Moscow, 1962. (Translated from French.)
Vygodchikov, G. V. “Nauchnye osnovy vaktsinno-syvorotochnogo dela.” In Mnogotomnoe rukovodstvo po mikrobiologii, klinike i epidemiologii infektsionnykh boleznei, vol. 3. Moscow, 1964. Pages 485-506.
Kravchenko, A. T., R. A. Saltykov, and F. F. Rezepov. Prakticheskoe rukovodstvo po primeneniiu biologic he skikh preparatov. Moscow, 1968.



A suspension of killed or attenuated bacteria or viruses or fractions thereof, injected to produce active immunity.


1. a suspension of dead, attenuated, or otherwise modified microorganisms (viruses, bacteria, or rickettsiae) for inoculation to produce immunity to a disease by stimulating the production of antibodies
2. (originally) a preparation of the virus of cowpox taken from infected cows and inoculated in humans to produce immunity to smallpox
3. of or relating to vaccination or vaccinia
4. Computing a piece of software designed to detect and remove computer viruses from a system
References in periodicals archive ?
Because of these developments, we sought to clarify changes in serotypes and in genetic antimicrobial resistance in isolates from adults with IPDs after PCV7 for children was introduced in Japan.
4% reduction in antibiotic prescriptions was recorded after the introduction of PCV7 at the Kaiser Permanente clinics in Northern California, as well as a 12.
There were 1,252 children born in the period May 1, 1997 to March 31, 2002, who were targeted by the PCV7 catch-up program.
We discerned IPD caused by PCV7 (4, 6B, 9V, 14, 18C, 19F, 23F), non-PCV7, PCV10-7 (present in PCV10 but not PCV7; 1, 5, 7F), non-PCV10, and PCV10 -related (6A, 6C, 6D, 7A, 7B, 7C, 9A, 9L, 9N, 18A, 18B, 18F, 19A, 19B, 19C, 23A, 23B) serotypes.
19, 20, 23) Based on WHO-defined radiological pneumonia, the adjusted efficacy for prevention of a first episode of pneumonia was 25% with PCV7 for intent-to-treat in the USA.
They found after routine use of the PCV7 by age two, the proportion of children who developed frequent ear infections and the proportion who needed pressure-equalizing tubes inserted in their ears, declined by 16% in Tennessee and 25% in New York.
The incidence of pneumococcal meningitis reported in Western Europe and the USA (8-9 per 100 000 child years) was similar prior to introduction of PCV7 (163) However, studies of pneumococcal meningitis from Africa demonstrate incidence rates among children <2 years of age that are much higher (40-43 per 100 000 child years) (8).
Due to the significant burden of pneumococcal disease and demonstrated vaccine efficacy, the World Health Organization (WHO) recommends the priority inclusion of PCV7 in national childhood immunization programs worldwide.
As mentioned earlier, ABCs closely tracked the decline in IPD in children after the introduction of PCV7 (Figure 1).
In the province of Quebec, free PCV7 was offered to high-risk children and those living in the two northern regions (Cree and Inuit) in October 2002, and four doses were recommended (respectively at 2, 4, 6 and 12-18 months of age).
Due to the significant burden of pneumococcal disease and demonstrated vaccine efficacy, WHO recommends the priority inclusion of PCV7 in national childhood immunization programs worldwide.